Current testing guidelines do not recommend population-based genetic testing for ovarian cancer, however population-based testing approaches may be effective in groups with a small number of common founder mutations such as the three BRCA1/2 variants in Ashkenazi Jews [86,87]. The gene discussed is BRCA1; the disease is ovarian cancer.